Home > Products > Novel inhibitors

Novel inhibitors

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DCC4014 Pbi-1393 Novel enhancer of Th1 type cytokine production and primary T cell activation
DCC4015 Pbiilh2 Pyridobenzimidazole infraluciferin, an analog of D-luciferin, increasing bioluminescence activity while maintaining nIR bioluminescence
DCC4016 P-bi-tat Novel αvβ3 inhibitor, showing excellent efficacy in a glioblastoma multiforme (GBM) mouse model
DCC4017 Pbs-1086 Novel dual inhibitor of the canonical and noncanonical NF-κB pathways, increasing the magnitude and duration of initial EGFR inhibitor response in multiple NSCLC models, decreasing PDHK1 expression, and suppressing phosphorylation of the PDHK1 protein sub
DCC4018 Pb-wut-01 Novel calcineurin inhibitor in the C. albicans cells, enhancing susceptibility of the cells
DCC4019 pc-046 Potent tubulin-binding agent with anti-tumor efficacy in hematologic cancers
DCC4020 Pc407-ws Water-soluble novel potential COX-2 inhibitor
DCC4021 Pcb153 Non-dioxin-like (NDL) congener
DCC4022 Pcb-te2p Novel Chelator for Cu-64
DCC4023 Pcc-0105002 Novel PSD95-nNOS inhibitor, disrupting the PSD95-nNOS interaction, attenuating neuropathic pain, decreasing SNL-induced spinal dorsal horn WDR neuron hyperexcitation
DCC4024 Pcc0208018 Novel activator of effector T cells, enhancing T cell proliferation and activation to release interferon gamma (IFN-γ) and interleukin-2 (IL-2) without blocking the programmed cell death 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) binding and not dire
DCC4025 P-cf3-diepp Novel α7 nAChR weak partial agonist, showing antinociceptive and anti-inflammatory properties
DCC4026 p-chloro-diphenyl Diselenide Organoselenium compound with antidepressant-like and memory enhancer actions
DCC4027 pcm126 Potent antagonist of the series disrupting EphA2-ephrinA1 interaction, blocking EphA2 phosphorylation in prostate cancer cells at low
DCC4028 p-come 102 Highly selective α1L adrenaline receptor agonist
DCC4029 Pcpma-(1r,2r)-22e Novel potent dopamine D3R agonist (Ki=4.1nM)
DCC4030 Pcpma-(1r,2r)-30q Novel potent and selective dopamine D3R partial agonist
DCC4031 Pcpma-(1s,2s)-22e Novel potent dopamine D3R antagonist
DCC4032 Pcsk9 Modulator Novel modulator of proprotein convertase subtilisin kexin like type 9 (PCSK9)
DCC4033 Pcsk9-in-4d Novel PCSK9 mRNA translation inhibitor
DCC4034 Pcsk9-in-4g Novel PCSK9 mRNA translation inhibitor
DCC4035 Pcsk9-in-8b Novel liver-targeted inhibitor of ribosomal synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9)
DCC4036 Pd-1 Inhibitor 16 Novel inhibitor of PD-I/PD-L1 interaction to be used as a negative immune checkpoint regulatory and antineoplastic agent
DCC4037 Pd-1/pd-l1 Antagonist D2 Novel potent PD-1/PD-L1 antagonist (IC50 of 16.17 nM), activating the antitumor immunity of T cells efficiently in PBMCs
DCC4038 Pd-1/pd-l1 Inhibitor 17 Novel bifunctional inhibitor of PD-1/PD-L1 interactions, promoting dimerization, internalization, and degradation of PD-L1, suppressing tumor growth in vivo by activating antitumor immunity
DCC4039 Pd-1/pd-l1 Inhibitor A30 Novel Potent Inhibitor of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction
DCC4040 Pd-1/pd-l1 Inhibitor Ch1 Novel inhibitor of PD-1/PD-L1 (IC 50 value of 56.58 nM), dose-dependently promoting HepG2 cell death in a co-culture model of HepG2/hPD-L1 and Jurkat T cells, effectively inhibiting tumor growth (TGI of 76.4% at 90 mg/kg) in an immune checkpoint humanized
DCC4041 Pd-1/pd-l1 Inhibitor P18 Novel potent programmed cell death-1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitor (IC50 9.1 nM)
DCC4042 Pd-128907 Hydrochloride Selective D3 dopamine receptor agonist
DCC4043 Pd-151242 Selective antagonist for human ETA receptors

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X